FGF23 and periodontitis: Future studies are needed both in Hyp mice and, at a longer scale, in humans, to explore the impact of FGF23 inhibition on the ECM proteins present in the treated dental tissues compared to untreated animals40 and patients.41 Overall, the benefits in the periodontium-supporting structures observed in treated mice suggest that burosumab may decrease the susceptibility of adult patients to periodontitis.